Effects of short-chain and saturated long-chain fatty acids on tumor growth - In vitro and experimental in vivo effects;Einflüsse kurzkettiger und gesättigter langkettiger fettsäuren auf das tumorwachstum - In-vitro- und experimentelle in-vivo-effekte

Aktuelle Ernahrungsmedizin

Volumn 33, Issue 5, 2008, Pages 225-230

  Holm, E ^a   Schade, I ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Nutrient pharmacology; Palmitic acid; Short chain fatty acids; Stearic acid; Tributyrin; Tumor growth

Indexed keywords

BUTYRIC ACID; PALMITIC ACID; STEARIC ACID; TRIBUTYRIN;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG HALF LIFE; DRUG INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; REVIEW; TUMOR CELL LINE; TUMOR GROWTH;

BACTERIA (MICROORGANISMS);

EID: 54849440848     PISSN: 03410501     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1067532     Document Type: Review

References (50)

1. Holm E. Stoffwechsel und Ernährung bei Tumorkrankheiten. Stuttgart, New York: Thieme, 2007
2. Breitkreutz R, Tesdal K, Jentschura D et al. Effects of a high-fat diet on body composition in cancer patients receiving chemotherapy: a randomized controlled study. Wien Klin Wochenschr 2005; 117: 685-692
3. Myzak MC, Dashwood RH. Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr Drug Targets 2006; 7: 443-452
4. Emenaker NJ, Calaf GM, Cox D et al. Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. J Nutr 2001; 131 (11 Suppl): 3041S-3046S
5. Matthews GM, Howarth GS, Butler RN. Short-Chain Fatty Acid Modulation of Apoptosis in the Kato III Human Gastric Carcinoma Cell Line. Cancer Biol Ther 2007; 5: 569-572
6. Comalada M, Bailon E, de Haro O et al. The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. J Cancer Res Clin Oncol 2006; 132: 487-497
7. Edelman MJ, Bauer K, Khanwani S et al. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemother Pharmacol 2003; 51: 439-444
8. Novogrodsky A, Dvir A, Ravid A et al. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 1983; 51: 9-14
9. Baradari V, Huether A, Hopfner M et al. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 2006; 13: 1237-1250
10. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors downregulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 2005; 25: 1608-1619
11. Farrow B, Rychahou P, O'Connor KL et al. Butyrate inhibits pancreatic cancer invasion. J Gastrointest Surg 2003; 7: 864-870
12. Gaschott T, Maassen CU, Stein J. Tributyrin, a butyrate precursor, impairs growth and induces apoptosis and differentiation in pancreatic cancer cells. Anticancer Res 2001; 21: 2815-2819
13. Gillenwater A, Zou CP, Zhong M et al. Effects of sodium butyrate on growth, differentiation, and apoptosis in head and neck squamous carcinoma cell lines. Head Neck 2000; 22: 247-256
14. Ito N, Sawa H, Nagane M et al. Inhibitory effects of sodium butyrate on proliferation and invasiveness of human glioma cells. Neurosurgery 2001; 49: 430-436
15. Kolar SS, Barhoumi R, Callaway ES et al. Synergy between docosahexaenoic acid and butyrate elicits p53-independent apoptosis via mitochondrial Ca(2+) accumulation in colonocytes. Am J Physiol Gastrointest Liver Physiol 2007; 293: G935-G943
16. Kuefer R, Hofer MD, Altug V et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 2004; 90: 535-541
17. Litvak DA, Hwang KO, Evers BM et al. Induction of apoptosis in human gastric cancer by sodium butyrate. Anticancer Res 2000; 20: 779-784
18. Louis M, Rosato RR, Brault L et al. The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. Int J Oncol 2004; 25: 1701-1711
19. Maier S, Reich E, Martin R et al. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines. Int J Cancer 2000; 88: 245-251
20. Ramos MG, Rabelo FL, Brumatti G et al. Butyrate increases apoptosis induced by different antineoplastic drugs in monocytic leukemia cells. Chemotherapy 2004; 50: 221-228
21. Rozental R, Faharani R, Yu Y et al. Sodium butyrate induces apoptosis in MSN neuroblastoma cells in a calcium independent pathway. Neurochem Res 2004; 29: 2125-2134
22. Schroder C, Eckert K, Maurer HR. Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro. Int J Oncol 1998; 13: 335-1340
23. Shao Y, Zhonghua G, Marks PA et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004; 101: 18030-18035
24. Sonnemann J, Kumar KS, Heesch S et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 2006; 28: 755-766
25. Yamamoto H, Fujimoto J, Okamoto E et al. Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer 1998; 76: 897-902
26. Avivi-Green C, Polak-Charcon S, Madar Z et al. Apoptosis cascade proteins are regulated in vivo by high intracolonic butyrate concentration: Correlation with colon cancer inhibition. Oncol Res 2000; 12: 83-95
27. Li X, Mikkelsen IM, Mortensen B et al. Butyrate reduces liver metastasis of rat colon carcinoma cells in vivo and resistance to oxidative stress in vitro. Clin Exp Metastasis 2004; 21: 331-338
28. Hara I, Miyake H, Hara S et al. Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity. Int J Oncol 2000; 17: 1213-1218
29. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-299
30. Kouraklis G, Theocharis S. Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol Rep 2006; 15: 489-494
31. Rada-Iglesias A, Enroth S, Ameur A et al. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Genome Res 2007; 17: 708-719
32. Miller AA, Kurschel E, Osieka R et al. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987; 23: 1283-1287
33. Conley BA, Egorin MJ, Tait N et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 1998; 4: 629-634
34. Su J, He L, Zhang N et al. Evaluation of tributyrin lipid emulsion with affinity to low-density lipoprotein: pharmacokinetics in adult male Wistar rats and cellular activity on Caco-2 and HepG2 cell lines. J Pharmacol Exp Ther 2006; 316: 62-70
35. Nkondjock A, Krewski D, Johnson KC et al. Specific fatty acid intake and the risk of pancreatic cancer in Canada. Br J Cancer 2005; 92: 971-977
36. Leosdottir M, Nilsson PM, Nilsson JA et al. Dietary fat intake and early mortality patterns - data from The Malmo Diet and Cancer Study. J Intern Med 2005; 258: 153-165
37. Tinsley IJ, Schmitz JA, Pierce DA. Influence of dietary fatty acids on the incidence of mammary tumors in the C3H mouse. Cancer Res 1981; 41: 1460-1465
38. Buckman DK, Chapkin RS, Erickson KL. 2007 Modulation of mouse mammary tumor growth and linoleate enhanced metastasis by oleate. J Nutr 1990; 120: 148-157
39. Gleeson RP, Ayub M, Wright JT et al. Fatty acid control of growth of human cervical and endometrial cancer cells. Br J Cancer 1990; 61: 500-503
40. Hardy S, Langelier Y, Prentki M. Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer Res 2000; 60: 6353-6358
41. Rose DP, Connolly JM. Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res 1990; 50: 7139-7144
42. Wicha MS, Liotta LA, Kidwell WR. Effects of free fatty acids on the growth of normal and neoplastic rat mammary epithelial cells. Cancer Res 1979; 39: 426-435
43. Wickramasinghe NS, Jo H, McDonald JM et al. Stearate inhibition of breast cancer cell proliferation. A mechanism involving epidermal growth factor receptor and G-proteins. Am J Pathol 1996; 148: 987-995
44. Weber G, Lea MA, Convery HJ et al. Regulation of gluconeogenesis and glycolysis: studies of mechanisms controlling enzyme activity. Adv Enzyme Regul 1967; 5: 257-300
45. Marchut E, Guminska M, Kedryna T. The inhibitory effect of various fatty acids on aerobic glycolysis in Ehrlich ascites tumour cells. Acta Biochem Pol 1986; 13: 7-16
46. Eigenbrodt E, Reinacher M, Scheefers-Borchel U et al. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumour cells. Clin Rev Oncogen 1992; 3: 91-115
47. Beckers A, Organe S, Timmermans L et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 2007; 67: 8180-8187
48. Chajes V, Cambot M, Moreau K et al. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res 2006; 66: 5287-5294
49. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000; 16: 202-208
50. Pizer ES, Jackisch C, Wood FD et al. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 1996; 56: 2745-2747